Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

OXGN:US

1.4250 USD 0.0150 1.04%

As of 15:49:15 ET on 05/22/2015.

Snapshot for OXiGENE Inc (OXGN)

Open: 1.4600 Day's Range: 1.4000 - 1.4600 Volume: 251,769
Previous Close: 1.4400 52wk Range: 1.3100 - 3.0700 1-Yr Rtn: -52.35%

Stock Chart for OXGN

No chart data available.
  • OXGN:US 1.4250
  • 1D
  • 1M
  • 1Y
1.4400
Interactive OXGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OXGN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.6500
Est. EPS (USD) (12/2015) -0.5950
Est. PEG Ratio -
Market Cap (M USD) 38.09
Shares Outstanding (M) 26.54
30 Day Average Volume 429,022
Price/Book (mrq) 1.0611
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OXGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OXGN

OXiGENE Inc. is a pharmaceutical company that develops therapeutics to treat cancer and eye diseases. The Company focuses on the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.

William D Schwieterman "Bill"President/CEODavid J Chaplin "Dai"Chief Scientific Officer
Barbara RichingVP/CFO
More Company Profile & Key Executives for OXGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil